FDA clears Draximage's BrachySeed pd-103 implant:
This article was originally published in Clinica
Draximage has received US FDA 510(k) clearance to market its palladium-103 brachytherapy implant, BrachySeed Pd-103, for treating prostate cancer and other localised tumours, such as those of the breast, head, neck, lung, pancreas and uterus. Pending approval from the US Nuclear Regulatory Commission, the firm hopes to sell the product through its distribution partner Cytogen, later this year. Draximage, a subsidiary of Draxis Health (Mississauga, Ontario), already markets an iodine-125 BrachySeed implant in the US and Canada. It says it will be one of the few companies to offer both palladium and iodine implants.